Sign In
Buy COYA
$4.86
-0.405 (-7.70%)
At Close: Jul 13, 2026
Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year?
10:41am, Tuesday, 30'th Jun 2026
Here is how Coya Therapeutics, Inc. (COYA) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
09:00am, Thursday, 18'th Jun 2026
[url="]Coya Therapeutics, Inc.[/url] (NASDAQ: COYA) (âCoyaâ or the âCompanyâ), a clinical-stage biotechnology company developing biologics intended to
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
08:00am, Thursday, 18'th Jun 2026
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) functi
[url="]Coya Therapeutics, Inc.[/url] (NASDAQ: COYA) (âCoyaâ or the âCompanyâ), a clinical-stage biotechnology company developing biologics intended to
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) functi
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, annou
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
08:00am, Wednesday, 27'th May 2026
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) functi
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
07:35am, Tuesday, 12'th May 2026
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) functi
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cel
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Rating of “Moderate Buy” from Brokerages
04:10am, Saturday, 18'th Apr 2026
Shares of Coya Therapeutics, Inc. (NASDAQ: COYA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six analysts that are covering the stock, Marketbeat reports. One in
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, annou
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director
08:00am, Thursday, 02'nd Apr 2026
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) functi
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, annou
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results
08:00am, Monday, 16'th Mar 2026
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) functi
Coya Therapeutics (COYA) to Release Quarterly Earnings on Tuesday
02:30am, Tuesday, 10'th Mar 2026
Coya Therapeutics (NASDAQ: COYA - Get Free Report) is projected to announce its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect the company to announce earnings of ($0.
